Why the study?
Does optimal Time-in-Therapeutic Range (>75%) reduce adverse events in newly diagnosed atrial fibrillation patients on warfarin, independent of underlying renal function?
Population
7,738 newly diagnosed atrial fibrillation patients initiating treatment with warfarin, from the Stockholm…
Comparison
Warfarin therapy with optimal… vs Warfarin therapy with suboptimal…
Design
Cohort
Follow-up
median 254 days
Authors
Loading...
In newly diagnosed atrial fibrillation patients on warfarin, severe chronic kidney disease is associated with worse INR control, but maintaining a TTR >75% significantly reduces adverse events regardless of underlying renal function.
Does optimal Time-in-Therapeutic Range (>75%) reduce adverse events in newly diagnosed atrial fibrillation patients on warfarin, independent of underlying renal function?
In newly diagnosed atrial fibrillation patients on warfarin, severe chronic kidney disease is associated with worse INR control, but maintaining a TTR >75% significantly reduces adverse events regardless of underlying renal function.
Szummer et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: